CITED1 is the founding member of the CITED family of cofactors that are involved in regulating a wide variety of CBP/ p300-dependent transcriptional responses. In the present study, we show that the phosphorylation status of CITED1 changes during the cell cycle and affects its transcriptional cofactor activity. Tryptic mapping and mutagenesis studies identified five phosphorylated serine residues in CITED1. Phosphorylation of these residues did not affect CRM1-dependent nuclear export, but did decrease CITED1 binding to p300 and inhibited CITED1-dependent transactivation of Smad4 and p300. These results suggest that CITED1 functions as a cell cycle-dependent transcriptional cofactor whose activity is regulated by phosphorylation.
The CITED family of transcriptional cofactors consists of four members (CITED1-4, CITED1, -2, and -4 in mammals) that regulate diverse CBP/p300-dependent transcriptional responses (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . CITED1 is expressed in a variety of embryonic tissues including the heart, limb buds, hepatic primordia, and developing kidney (15, 16) . In the adult, CITED1 is expressed at high levels in papillary carcinoma of the thyroid gland (17, 18) , malignant melanoma (19, 20) , and Wilms tumor (21) , suggesting that it may play a role in the pathogenesis of certain tumors. Studies using CITED1 knock-out mice indicate that its expression in the extra-embryonic trophectoderm plays an essential role in regulating normal placental development (22) , whereas expression in the mammary gland is required for growth and branching of mammary epithelium at puberty (23) . Biochemical studies indicate that CITED1 selectively enhances transcriptional responses involving TGF-␤ 4 /Smad4 and estrogen receptor-␣, whereas it inhibits Wnt/␤-catenin-dependent responses (12, 13, 15) . These effects are dependent on interactions between CITED1 and CBP/p300, but the molecular mechanisms regulating CITED1-dependent transactivation have not been elucidated. In these studies we show that CITED1 exists in both an unphosphorylated and at least two phosphorylated forms, and that levels of both phosphoproteins are independently regulated over the course of the cell cycle. Mapping and functional evaluation of the dominant phosphorylated form of CITED1 found in interphase cells indicates that phosphorylation reduces CITED1-dependent transactivation of Smad4 and p300.ThisoccurswithoutaffectingthenormalprocessofCRM1-dependent nuclear export, but is associated with decreased binding of CITED1 to p300. These findings indicate that the transcriptional activity of CITED1 is regulated by phosphorylation in a cell cycle-dependent manner.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Cycle Synchronization-Human embryonic kidney (HEK) 293, human breast cancer MCF7, and the HepG2 hepatocellular carcinoma cells were obtained from the American Type Culture Collection, and B16-F1 murine melanoma cells were obtained from Isaiah Fidler (24) . NPA187 human papillary thyroid carcinoma cells were obtained from Guy Juillard, UCLA (25) . All cell lines were cultured at 37°C and 5% CO 2 in DMEM supplemented with 10% fetal bovine serum (FBS). HEK-293 cells were grown on plasticware coated with type 1 collagen (Rat tail, BD Biosciences) to increase adherence. Stable overexpression of FLAG-tagged CITED1 and the CITED1 S5A and S5E mutants in pcDNA3 (Invitrogen) or pEGFP-CITED1 (Clontech) was produced by transfection of the respective expression plasmids into HEK-293 and selection with 400 g/ml G418. These are referred to as HEK-CITED1 or HEK-GFP CITED1 cells, respectively. For cell cycle studies, cells were synchronized in G 0 by culturing for 48 h in serumfree medium (DMEM with 0.1% bovine serum albumin) (Ͼ70% G 0 /G 1 ) and S-phase by double thymidine block (Ͼ70% cells in S). After release from thymidine, block cells were blocked in M-phase by treatment with 100 nM nocodazole (Sigma) overnight (Ͼ90% G 2 /M-phase), as described (26) . Efficiency of cell cycle block was evaluated in preliminary studies by flow cytometry using propidium iodide staining, as described (27) . For M-phase release, loosely adherent mitotic cells were collected after gently tapping the plate, washed three times in phosphatebuffered saline and released from M-phase in DMEM with 10% FBS for various times, as indicated. The protein phosphatase inhibitor, okadaic acid (Calbiochem), was added to the cells at 10 nM concentration for the last 2 h after overnight treatment with nocodazole.
Expression Plasmids and Transcriptional Response AssaysAmino-terminal FLAG-tagged human CITED1 in pcDNA3 and the Gal4 DNA binding Smad4-(266 -552) fusion protein in pSG424 were generated in our laboratory (15, 28) ; the p5E1B-Luc Gal4 reporter construct was provided by Jeff Wrana (29) , and the full-length Gal4-p300 fusion protein construct obtained from Neil Perkins (30) . Serine to alanine (Ser 3 Ala) or glutamic acid (Ser 3 Glu) mutations at residues 16, 63, 67, 71, and 137 were generated sequentially using a PCR-based site-directed mutagenesis kit (Stratagene) on the FLAG-tagged human CITED1 expression plasmid, using primer sets shown in Table 1 . Sequence changes were confirmed by dideoxynucleotide sequencing. Transient transfection assays were performed on HEK-293 cells using Lipofectamine (Invitrogen), with transfection efficiency evaluated by cotransfecting with constitutively expressed pSV␤-galactosidase vector and subsequent enzyme activity assay. Transcriptional response assays were performed by cotransfecting the p5E1B-Luc Gal4 reporter construct with the Gal4 Smad4 or p300 fusion proteins, along with the FLAG-tagged CITED1 expression constructs, as previously described (15, 28) . Cells were washed after 4 -6 h, allowed to recover for 24 h in growth medium, serum-starved, and treated for 18 h with or without 10 ng/ml TGF-␤1 (R&D Systems). Luciferase and ␤-galactosidase activities in the cell lysates were determined, and luciferase activities were normalized for ␤-galactosidase expression to correct for transfection efficiency, as described (31) . All assays were performed in triplicate and values represented as mean Ϯ S.E. of three independent transfections. Experiments were repeated twice with similar results. Expression of FLAG-tagged CITED1 mutants in the same cell lysates was determined by Western blot using M2 anti-FLAG monoclonal antibody (Sigma).
Western Blot and Two-dimensional Gel ElectrophoresisWestern blots were performed after separating lysates and/or immunoprecipitated proteins by SDS-PAGE and transfer to polyvinylidene difluoride membranes using anti-CITED1 mouse monoclonal antibody clone 2H6 (15) , mouse anti-p300 (Upstate, clone RW128), or mouse anti-␤-actin (Sigma, clone AC74), as indicated. For two-dimensional gel electrophoresis, HEK-CITED1 immunoprecipitates were treated with or without alkaline phosphatase (as outlined below), and resuspended in 8 M urea buffer (8 M urea, 1% CHAPS, 20 mM dithiothreitol) with 0.5% ampholytes (Bio-Rad, Ready Strip buffer pH 3.9 -5.1). These were separated in the first dimension by isoelectric focusing using a non-linear, immobilized pH gradient strip gel, pH range 3.0 -5.6 (Amersham Biosciences), using the Invitrogen ZOOM immobilized pH gradient runner system at 100 V for 30 min. For the second dimension, focused immobilized pH gradient strips were equilibrated in NuPAGE lithium dodecyl sulfate sample buffer (Invitrogen Corp.) in the presence of NuPAGE sample reducing agent (Invitrogen Corp.) for 15 min, and further incubated in lithium dodecyl sulfate sample buffer in the presence of 125 mM iodoacetamide for 15 min. The strips were placed on 12% BisTris gels and embedded in 0.5% agarose, and after separation transferred to polyvinylidene difluoride membranes for Western blot.
Subcellular Fractionation-Subcellular fractionation was performed by differential centrifugation of asynchronous MCF7 and HEK-CITED1 cells following homogenization in hypotonic media, as previously described (32) . Nuclear fractions were separated after centrifugation at 1,000 ϫ g for 10 min, whereas membrane and free cytosolic fractions were separated after centrifugation at 100,000 ϫ g for 45 min. Fractions were separated by SDS-PAGE and CITED1 detected by Western blot using mouse anti-CITED1 monoclonal antibody (2H6). Equal protein loading of each fraction was estimated by Bradford assay.
Metabolic Labeling-For metabolic labeling studies, MCF7 and HEK-CITED1 cells were incubated in phosphate-free DMEM with 10% dialyzed FBS for 30 min before labeling with 0.5 mCi/ml [ 32 P]orthophosphate for 4 h. After extensive washing, cells were lysed in Trion X-100 lysis buffer (1% Triton X-100, 150 mM NaCl, 25 mM HEPES, 5 mM EDTA, and 10% glycerol) along with 50 mg/ml of the protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride (Sigma), and the phosphatase inhibitors 50 mM sodium fluoride and 1 M sodium orthovanadate. Lysates were then clarified and pre-cleared with protein A/G-agarose beads (Santa Cruz Biotechnology). Immunoprecipitation was performed for 4 h on ice using an affinity purified rabbit anti-CITED1 antibody raised against a unique COOH-terminal peptide sequence (J) (15) . After addition of protein A/G-agarose beads, the immunoprecipitates were extensively washed in ice-cold Triton X-100 lysis buffer, sepa- 
GCAGAATCACTCGAACCTTCTGCTGGT CACCAGCAGAAGGTTCGAGTGATTCTG rated by SDS-PAGE, and transferred to polyvinylidene difluoride membranes for autoradiography. Phosphoamino Acid Analysis-Phosphoamino acid analysis of the HEK-FLAG CITED1 immunoprecipitates was performed on the 32 P-labeled M-phase CITED1 bands detected by autoradiography, as previously described (33) . For phosphoamino acid analysis, the cut polyvinylidene difluoride membrane was incubated with 6 M HCl at 110°C for 1 h, the supernatant removed, vacuum dried, and resuspended in pH 1.9 buffer (2.2% formic acid with 7.8% glacial acetic acid) along with phosphoserine, phosphothreonine, and phosphotyrosine standards (Sigma) at 1 mg/ml. After spotting on to TLC plates, amino acids were separated using a Hunter thin layer electrophoresis system in pH 1.9 buffer in the first dimension, followed by pH 3.5 buffer (10% glacial acetic acid, 1% pyridine, and 1 mM EDTA) in the second dimension. The phosphoamino acid standards were visualized by spraying with 0.25% ninhydrin in acetone, and 32 P-labeled amino acids were visualized by autoradiography of the TLC plate.
Tryptic Mapping-Tryptic mapping was performed on the excised 32 P-labeled S-phase and M-phase CITED1 bands detected by autoradiography, as previously described (33) . These were incubated with methanol, and then blocked with 50 mM NH 4 HCO 3 containing 0.1% Tween 20 for 30 min at room temperature. Phosphoproteins were digested twice with 10 l of 1 mg/ml L-1-tosylamido-2-phenylethyl chloromethyl ketone trypsin (Promega) in 100 l of NH 4 HCO 3 at 37°C overnight, and oxidized with performic acid. Released peptides were first separated by electrophoresis on TLC plates at pH 1.9, using the Hunter thin-layer electrophoresis system (model HTLE-7000), at 1000 V for 45 min. Separation in the second dimension was performed by ascending chromatography in n-butyl alcohol (37.5%), pyridine (25%), and acetic acid (7.5%). Resolved phosphopeptides were visualized by autoradiography using BioMax MS high speed film (Eastman Kodak Co.).
Immunofluorescence Studies-E15.5 mouse kidneys were fixed for 4 h in 4% paraformaldehyde, embedded, and sectioned. After blocking in 10% goat serum, sections were incubated overnight at 4°C with mouse monoclonal anti-E-cadherin (BD Biosciences, clone 32) and rabbit polyclonal anti-CITED1 (Neomarkers). These were detected using fluorescein-conjugated horse antimouse (Vector Labs) and rhodamine-conjugated goat anti-rabbit antibodies (Jackson ImmunoResearch), and visualized using a Nikon Eclipse epifluorescence microscope. For immunofluorescence staining of cultured cells, HEK-293 and HEK-CITED1 cells were plated onto glass chamber slides coated with type I collagen (Rat Tail, BD Biosciences), fixed in 3% paraformaldehyde in phosphate-buffered saline with 2% sucrose, and permeabilized with 0.2% Triton X, as described (34) . After blocking, chambers were incubated overnight at 4°C with rabbit anti-CITED1 (Neomarkers) or FLAG M2 monoclonal antibodies (Sigma), and detected using fluorescein isothiocyanate-conjugated anti-rabbit or mouse antibodies (Jackson ImmunoResearch), respectively. Nuclear structures were visualized using the far red nuclear stain TO-PRO-3 (Molecular Probes). For subcellular localization studies in live cells, GFP-tagged CITED1 constructs were either transiently transfected into C2C12 cells or stably transfected into HEK-293 cells, and live cells were visualized using an inverted confocal microscope using the appropriate filter sets. Images were acquired before and 30 min after treatment with 1 ng/ml leptomycin B (Sigma), to inhibit CRM-dependent nuclear export.
RESULTS

CITED1 Is Phosphorylated in a Cell Cycle-dependent Manner-
We evaluated endogenous CITED1 expression in three cell lines. CITED1 appears as a doublet in B16 melanoma and MCF7 breast carcinoma cells synchronized in S-phase. There was a further shift in mobility in these cells and in NPA187 papillary thyroid carcinoma cells synchronized in M-phase FIGURE 1. CITED1 is phosphorylated during mitosis. A, mitotic phosphorylation of endogenous CITED1. CITED1 was immunoprecipitated (IP) from B16 melanoma and NPA187 papillary thyroid carcinoma and MCF7 breast carcinoma cell lysates using rabbit anti-CITED1 antibody. Cells were synchronized in S-phase or M-phase, and treated Ϯ10 nM okadaic acid for 2 h. Immunoprecipitates were also incubated with or without alkaline phosphatase (Alk Phos) before separation by SDS-PAGE, as indicated. CITED1 was detected in the immunoprecipitates by Western blot using mouse anti-CITED1 monoclonal antibody (2H6). B and C, phosphorylation-dependent changes in CITED1 mobility in HEK-CITED1 cells. FLAG-tagged CITED1 was immunoprecipitated using anti-FLAG M2-agarose affinity resin from HEK-CITED1 cells treated as outlined above, separated by SDS-PAGE (B) or two-dimensional gel electrophoresis (isoelectric focusing and SDS-PAGE) (C), and detected by Western blot using the 2H6 antibody. Arrows indicate the dominant CITED1 phosphoproteins, pCITED1 and ppCITED1. (Fig. 1A, lanes 1 and 2) . This mobility shift was further enhanced by incubating M-phase cells with okadaic acid (Fig.  1A, lane 3) . This suggests that M-phase phosphorylation of CITED1 is regulated either directly or indirectly by an okadaic acid-sensitive protein phosphatase. To determine whether these changes in mobility resulted from protein phosphorylation, M-phase CITED1 immunoprecipitates were dephosphorylated by incubation with alkaline phosphatase. This treatment completely reversed the M-phase mobility shift, resulting in a single CITED1 band (Fig. 1A, lane 4) .
We compared changes in CITED1 mobility in S-phase and M-phase synchronized HEK-293 cells (which express low levels of endogenous CITED1 (15)) stably overexpressing FLAGtagged CITED1 (HEK-CITED1 cells). In these cells, CITED1 clearly migrated as a doublet in S-phase synchronized cells, and underwent a further shift in mobility in M-phase cells (Fig. 1B) . This effect was further accentuated by incubating the cells with okadaic acid prior to lysis. An identical pattern of CITED1 mobility was seen in cells arrested in M-phase using Taxol (data not shown). As in the previous studies, incubation of the immunoprecipitates with alkaline phosphatase reversed the M-phase mobility shift, resulting in a single CITED1 band (Fig. 1B) . The S-phase doublet also disappeared with -phosphatase treatment (see Fig. 4C ). Separation of CITED1 by two-dimensional gel electrophoresis (isoelectric focusing and SDS-PAGE) confirmed the presence of two CITED1 phosphoproteins in S-phase-and M-phase-synchronized cells that were sensitive to alkaline phosphatase treatment (Fig. 1C) . Throughout the rest of the article we will refer to the intermediate mobility phosphorylated form of CITED1 as "pCITED1," and the upper, hyperphosphorylated band seen in mitotic cells as "ppCITED1" (Fig. 1, B and C, arrows) .
To evaluate the regulation of these CITED1 phosphoproteins during progression of the cell cycle, HEK-CITED1 cells were synchronized in S-phase (Ͼ70% S-phase), G 0 (Ͼ70% G 0 /G 1 ), or M-phase (Ͼ90% G 2 /M), and released in medium containing 10% serum for various time periods. Whereas the level of pCITED1 was only slightly increased after release from thymidine block, the relative level of pCITED1 was reduced after prolonged serum starvation and strongly up-regulated after release in 10% serum for 8 h (Fig. 2A) . In contrast, cells released from M-phase showed no change in the relative level of pCITED1, but there was a rapid reduction in levels of ppCITED1 following release (Fig. 2B) . Taken together, these findings indicate that CITED1 exists in both unphosphorylated and at least two phosphorylated forms, and that levels of these phosphoproteins are dynamically regulated over the course of the cell cycle.
Mapping CITED1 Phosphorylation Sites-Having established that CITED1 phosphorylation is regulated in a cell cycledependent manner, we sought to map the phosphorylation , washed, and released in medium containing 10% FBS. CITED1 was detected by Western blot in cell lysates using 2H6 antibody, and ␤-actin was detected as a loading control. B, CITED1 is dephosphorylated following mitotic release. HEK-CITED1 cells were synchronized in M-phase using nocodazole, washed, and replated in DMEM with 10% FBS for the indicated time periods before lysis. CITED1 expression was detected in the lysates by Western blot using the 2H6 antibody. sites. [ 32 P]Orthophosphate labeling of MCF7 and HEK-CIT-ED1 cells confirmed that CITED1 was phosphorylated both in S-and M-phase-arrested cells (Fig. 3A) . Phosphoamino acid analysis of the CITED1 band from mitotic HEK-CITED1 cells only detected phosphoserine residues (Fig. 3B) . To characterize these phosphorylation sites further, we performed tryptic mapping of the [ 32 P]orthophosphate-labeled CITED1 bands from S-phase-and M-phase-synchronized HEK-CITED1 cells. Separation of the tryptic peptides by electrophoresis and chromatography identified three dominant 32 P-labeled CITED1 peptides in S-phase cells (Fig. 3C, spots 1-3) . The same peptides appeared in M-phase cell preparations (confirmed when S-phase and M-phase digests were mixed), although one of the spots (spot 2) showed increased mobility along the x axis in M-phase (migrating toward the positive electrode). In addition, a single negatively charged, hydrophobic phosphopeptide appeared in mitotic cells, which was not seen in S-phase preparations (spot 4). These data confirm that CITED1 exists in two phosphorylated forms: a phosphorylated form found in S-and M-phase cells containing three phosphorylated tryptic peptides, and a hyperphosphorylated form that is only found in M-phase cells containing an additional phosphorylated tryptic peptide.
CITED1 contains a number of potential serine phosphorylation sites. Six of these residues are conserved in human, mouse, and rat CITED1 sequences (Ser-16, Ser-63, Ser-67, Ser-71, Ser-137, and Ser-139), and five of these have predicted phosphorylation site scores of greater than 90% (Ser-16, Ser-63, Ser-67, Ser-71, and Ser-137) (NetPhos 2.0). We therefore explored the effects of individual and combinatorial mutations of these five serine residues on CITED1 mobility by Western blot. Whereas most of these mutations either individually or in combination gave rise to two M-phase bands (as opposed to the three seen with wild type CITED1), only the combination of mutations at residues Ser-16, Ser-63, Ser-67, Ser-71, and Ser-137 showed no change in mobility with mitosis ( Fig. 4A shows a representative selection of combinatorial mutations that were studied). We will refer to this combined mutant construct as CITED1 S5A for the remainder of the text. Introduction of glutamic acid residues at these sites to generate the phosphomimetic mutant, CITED1 S5E, gave rise to a single, low mobility band (Fig. 4B ).
-Phosphatase treatment of anti-FLAG immunoprecipitates from these cells had no significant effect on mobility of the dominant CITED1 S5A and S5E bands in S-or M-phase synchronized cells when compared with wild type CITED1 (Fig.  4C ). There was, however, a low mobility band seen with both of the CITED1 mutations in M-phase cells that was lost following -phosphatase treatment (Fig. 4C, arrow) . Whereas this was only seen in concentrated immunoprecipitates from M-phasesynchronized cells (compare lysates in Fig. 4, A and B) , it indicates that there is a minor M-phase CITED1 phosphorylation site that is not blocked by the CITED1 S5A and S5E mutations.
To define the precise effects of mutating these five serine residues on S-and M-phase phosphorylation, we evaluated phosphotryptic maps of [ 32 P]orthophosphate-labeled CITED1 bands from HEK-293 cells overexpressing CITED1 S5A. These studies showed that the S5A mutation prevented phosphorylation of the three dominant 32 P-labeled CITED1 peptides seen in S-and M-phase cells (Fig. 5A, spots 1-3 ). This is consistent with the predicted tryptic fragment map of CITED1 indicating that the five phosphorylated serine residues are dispersed across three separate predicted tryptic fragments (Fig. 5B , red dotted lines and arrows). However, these studies also demonstrated that there were two additional M-phase tryptic phosphopeptides in the CITED1 S5A preparations (Fig. 5A, spots A and B) . Mixing M-phase digests from wild type CITED1 and the S5A mutation suggests that one of the peptides (spot A) corresponds to the negatively charged M-phase phosphopeptide identified in the previous CITED1 tryptic map (Fig. 3C, spot 4) . The additional phosphopeptide (spot B) did not overlay with any of the A, CITED1 mutants that prevent phosphorylation. Five conserved, potential serine phosphorylation sites were identified in CITED1 using NetPhos and mutated in various combinations to alanine residues. These were stably transfected in HEK-293 cells, and comparative analysis of CITED1 mobility shifts in M-phase cells were determined by Western blot using the 2H6 antibody. Asterisk (*) indicates the only mutant that showed no mobility shift in mitosis. This mutant is referred to as CITED1 S5A. B, effects of CITED1 S5A and S5E on S-and M-phase phosphorylation events. All five serine phosphorylation sites were mutated to alanine (CITED S5A) or glutamic acid residues (CITED1 S5E). These were stably transfected in HEK-293 cells, and comparative analysis of SDS-PAGE mobility of CITED1 was determined by Western blot in the cell lysates from S-and M-phase cells. WT, wild type. C, CITED1 S5A and S5E mutations block S-phase but not M-phase phosphorylation of CITED1. HEK-293 cells overexpressing FLAG-tagged CITED1, CITED1 S5A, or CITED1 S5E were synchronized in S-or M-phase, lysed, immunoprecipitated, and incubated with -phosphatase, as indicated. The small arrow indicates a minor phosphatase-sensitive band that appears in M-phase immunoprecipitates.
wild type CITED1 phosphopeptides, and is likely to represent an artificial M-phase phosphorylation site that only occurs when the five serine residues are mutated. These findings indicate that CITED1 S5A blocks the common S-and M-phase phosphorylation sites in CITED1, but does not prevent the additional M-phase phosphorylation event. Subcellular Localization of CITED1 Is Driven by CRM1-dependent Nuclear Export-CITED1 is known to have differing subcellular localization in different cell types (14, 17, 20, 23) . One explanation for the effects of the phosphorylation mutations might therefore be that they influence the proportion of CITED1 localized in the nucleus. To evaluate this we first needed to determine the normal pattern and regulation of subcellular localization of CITED1.
Initial studies examined the endogenous localization of CIT-ED1 in embryonic kidney cells (from which HEK-293 cells are derived) using immunofluorescence. As previously described, CITED1 was expressed in the cap mesenchyme cells of the developing kidney (15) , predominantly within the cytoplasmic compartment of these cells (Fig. 6A) . More detailed analysis indicates that some CITED1 was also localized in the nucleus (Fig. 6B, inset) . To evaluate the localization of CITED1 in HEK-CITED1 cells, we performed immunofluorescence analysis of CITED1 using two different antibodies. These studies demonstrated that most, but not all of the overexpressed CITED1 was localized within the cytoplasmic compartment of these cells (Fig. 6, C-E) . HEK-293 cells were used as a negative control as they express low levels of endogenous CITED1, undetectable in these studies. Subcellular fractionation studies confirmed that although most of the CITED1 was located in the free cytosolic fraction of cell lysates, ϳ5% was present in the nuclear compartment of HEK-CITED1 and MCF7 cells (Fig. 6F) .
To determine the mechanism regulating cytoplasmic localization of CITED1, we transiently overexpressed GFP-tagged CITED1 constructs in C2C12 myoblasts and evaluated localization before and after treatment with leptomycin B. Wild type CITED1 was predominantly localized in the cytoplasm and became localized in the nucleus following treatment with leptomycin B (Fig. 6I , ϩ/ϪLB). GFP alone and GFP-tagged NFATc were included as negative and positive controls, respectively (Fig. 6, G and H) . Identical results were obtained in HEK-293 cells stably overexpressing GFP-CITED1 (see Fig. 7A ). As leptomycin B is a specific inhibitor of CRM1-dependent nuclear export (35) , these findings indicate that the dominant cytoplasmic localization of CITED1 is maintained by CRM1-dependent nuclear export.
In light of these findings, we went on to determine whether CITED1 contains an active nuclear export signal that might be modified by phosphorylation. Inspection of the amino acid sequence of CITED1 reveals the presence of three potential consensus NES motifs, ⌽ X 2-3 ⌽ X 2-3 ⌽ X 1-2 ⌽, where ⌽ ϭ Leu, Ile, Val, Phe, or Met, and X ϭ any amino acid (36) . One NES sequence is located in the CR1 domain ( 91 LLASMQLQKL 100 ) and there are two within the CR2 domain, one complete ( 158 LMSLVVELGL 167 ) and the other partial ( 169 RANELPELWL 178 ). All three are conserved within the two other members of the mammalian CITED family, CIT-ED2 and CITED4. Mutational analysis revealed that only the COOH-terminal NES sequence within the CR2 domain of CIT-ED1 was functionally active ( 158 LMSLVVELGL 167 ) (Fig. 6,  J-L) . Thus CITED1 contains a single, functional NES within its CR2 domain that mediates CRM1-dependent nuclear export.
Phosphorylation Does Not Affect Subcellular Localization of CITED1-Having established the normal mechanism regulating subcellular localization of CITED1, we went on to determine whether this response was modified by CITED1 phosphorylation. For these studies we stably overexpressed GFP-tagged wild type CITED1 and the CITED1 S5A and CITED1 S5E mutants in HEK-293 cells, and evaluated subcellular localization basally and in response to leptomycin B. As expected, wild type CITED1 was predominantly localized in the cytoplasm and translocated to the nucleus following treatment with leptomycin B (Fig. 7A) . Like wild type CITED1, the CITED1 S5A and S5E mutants were dominantly localized in the cytoplasm 1-4) . B, schematic representation of CITED1 phosphorylation sites. These are shown in relation to conserved domains found in other CITED family members (Conserved Regions 1 and 2, CR1 and CR2), and established functional and protein interaction domains in CITED1 (SID, Smad4 interaction domain; ER␣, estrogen receptor ␣). Predicted phosphorylated tryptic peptides are illustrated with dotted lines and arrows. and underwent rapid nuclear localization following treatment with leptomycin B (Fig. 7, B and C) . The findings indicate that phosphorylation does not interfere with NES-dependent nuclear export of CITED1.
Phosphorylation Inhibits CITED1-dependent Transactivation-As the phosphorylation state of CITED1 does not influence its subcellular localization, we went on to evaluate whether phosphorylation had a direct effect on the transcriptional coactivator activity of CITED1. To this end we compared the effect of overexpressing wild type CITED1 with CITED1 S5A and CITED1 S5E on an established CITED1-dependent transactivation response. Consistent with our previous data (12, 15) , wild type CITED1 enhanced the TGF-␤-activated transcriptional activity of the Gal4-Smad4-(266 -552) fusion protein in HEK-293 cells (Fig. 8A) . The S5A mutant showed stronger transcriptional activity than wild type CITED1, whereas the phosphomimetic S5E mutant only weakly transactivated the Gal4-Smad4 fusion protein. All three forms of CIT-ED1 were detected in cell lysates from these experiments at approximately equal levels (Fig. 8A, inset) , indicating that differential effects of the CITED1 mutants do not result from differences in protein expression. As transactivation of Smad4 is dependent on physical and functional interactions between CITED1 and the CBP/p300 coactivators (12), we sought to FIGURE 6 . Subcellular localization of CITED1 is regulated by CRM1-dependent nuclear export. A and B, localization of CITED1 in the metanephric mesenchyme. E15.5 embryonic mouse kidneys were fixed and expression of E-cadherin (green) and CITED1 (red ) detected by two-color immunofluorescence microscopy using mouse (E-cadherin) and rabbit (CITED1) antibodies, as indicated. B is an enlargement of the inset indicated in A. C-E, subcellular localization of CITED1 in HEK-CITED1 cells. Overexpressed CITED1 was detected using rabbit anti-CITED1 antibodies (Neomarkers) in asynchronous HEK-293 (C ) and HEK-CITED1 cells (D), or with mouse anti-FLAG antibodies (E ), and visualized with fluorescein isothiocyanate-conjugated secondary antibodies (green). HEK-293 cells were included as a negative control for CITED1 antibody staining as these cells express very low levels of endogenous CITED1. Nuclear structures were visualized using the far red nuclear stain TO-PRO-3 (red). F, subcellular fractionation of CITED1. Studies were performed by differential centrifugation of asynchronous MCF7 and HEK-CITED1 cell lysates into nuclear, membrane, and free cytosolic fractions, and CITED1 was detected by Western blot using the 2H6 antibody. Equal protein loading of each fraction was estimated by Bradford assay. G-L, CITED1 contains a CRM1-dependent leucine-rich NES. GFP-tagged controls (GFP alone (G) and as a positive control GFP-NFATc (H), wild type CITED1 (I), and the CITED1 NES mutant constructs (CITED1 L91A/M95A (J), CITED1 L165A/L167A (K), and CITED1 L176A/L178A (L)) were transiently transfected into mouse C2C12 myoblasts and GFP was detected in live cells. 200 -1000 transiently transfected cells were assessed for GFP expression for each construct, and the graphs represent the proportion of cells with expression predominantly in the nucleus alone (N, black bars), in both nucleus and cytoplasm (NC, gray bars) or predominantly in the cytoplasm alone (C, white bars). Leptomycin B (LB) treatment at 1 ng/ml was used to specifically inhibit CRM1-dependent nuclear export.
determine whether these CITED1 mutants had similar transactivation effects on p300. As predicted, CITED1 enhanced transcriptional activity of a Gal4 p300 fusion protein (Fig. 8B) . This response was significantly increased by the CITED1 S5A mutation, and whereas CITED1 S5E still activated Gal4 p300, this effect was less pronounced than with wild type CITED1. These findings indicate that phosphorylation inhibits CITED1-dependent transactivation of Smad4 and p300.
Phosphorylation of CITED1 Interferes with p300 Binding-As binding to the CBP/p300 coactivators plays an essential role in mediating different CITED1-dependent transactivation responses (12, 13, 15) , we went on to determine whether these phosphorylation site mutants showed altered binding to p300. As expected, immunoprecipitation of FLAG-tagged CITED1 constructs showed that endogenous p300 formed a complex with wild type CITED1 (Fig. 9, IP FLAG, top panel) . This interaction was enhanced with the CITED1 S5A mutation, whereas there was decreased p300 in the CIT-ED1 S5E immunoprecipitates. Conversely, immunoprecipitation of p300 showed that CITED1 S5A interacted more strongly with p300 than wild type CITED1, and there was no detectable interaction with CITED1 S5E (Fig. 9, IP p300, middle panel) . These studies also demonstrated that the dominant form of wild type CITED1 that interacted with p300 corresponds to the high mobility, unphosphorylated CITED1 band identified in our earlier studies.
DISCUSSION
These studies provide the first evidence that CITED1 functions as a cell cycle-dependent transcriptional cofactor whose activity is regulated by phosphorylation. We show that CITED1 exists in both an unphosphorylated and at least two phosphorylated forms, and that levels of these phosphoproteins are independently regulated over the course of the cell cycle. Phosphorylation of CITED1 is increased in interphase cells as they are released from G 0 , and there is a hyperphosphorylated form of CITED1 that only appears in M-phase cells and is rapidly dephosphorylated following mitotic release.
Having established that the level of CITED1 phosphorylation is regulated during the cell cycle, we mapped potential phosphorylation sites to study the effects of CITED1 phosphorylation on its functional activity.
32 P-Labeled tryptic maps of CITED1 from S-phase and M-phase cells showed that there was a common pattern of phosphopeptides in both S-phase and M-phase cells, with an additional phosphopeptide appearing in mitotic cells. These findings indicate that S-phase and M-phase cells contain a common CITED1 phosphoprotein and that this phosphoprotein undergoes further phosphorylation during M-phase to generate the hyperphosphorylated form of CITED1.
Mapping the phosphorylation sites in CITED1 identified five serine residues that are conserved in human, mouse, and rat CITED1 sequences (Ser-16, Ser-63, Ser-67, Ser-71, and Ser-137). Tryptic mapping indicates that these correspond to the FIGURE 7. CITED1 S5A and S5E mutations do not affect subcellular localization of CITED1. GFP-tagged wild type (WT ), S5A, and S5E CITED1 constructs were stably transfected into HEK-293 cells, and GFP-tagged CITED1 fusion proteins were detected in live cells by confocal microscopy before and 30 min after treatment with 1 ng/ml leptomycin B (LB). FIGURE 8. Effect of CITED1 phosphorylation site mutations on transactivating activity of CITED1. A, transactivation of Smad4. HEK-293 cells were transiently transfected with a Gal4 binding luciferase reporter, the Gal4 DNA binding Smad4-(266 -552) fusion protein, and two concentrations of the FLAG-tagged wild type (WT ), S5A or S5E CITED1 expression constructs (0.125 and 0.25 g/well). Cells were treated with 10 ng/ml TGF-␤1 for 18 h prior to lysis, and transfection efficiency was evaluated by cotransfecting pSV-␤-galactosidase and enzyme activity assay. Inset shows CITED1 expression in cell lysates determined by Western blot using anti-FLAG M2 antibodies. B, transactivation of p300. Studies were repeated under identical conditions (without TGF-␤ treatment) using a Gal4-p300 fusion construct. Results are expressed as mean Ϯ S.E. of corrected luciferase values in triplicate. Student's t test, p Ͻ 0.05; *, no CITED1 versus WT CITED1; **, WT CITED1 versus S5A; ***, WT CITED1 versus S5E.
common phosphorylation sites found in both the phosphorylated and hyperphosphorylated forms of CITED1. The location of these phosphorylation sites does not provide insight into their functional role as they do not occur in any of the established functional domains of this protein. Specifically, these are outside the NH 2 -terminal Smad4 (SID) and COOH-terminal CBP/p300 (CR2) interaction domains (12, 13, 15) . In addition our studies indicate that these sites do not overlap or functionally interfere with the active nuclear export signal that we identified within the CR2 domain the protein ( 158 LMSLV-VELGL 167 ). However, functional studies using alanine and glutamic acid phosphorylation site substitution mutants indicate that phosphorylation of these residues inhibits transactivation of Smad4 and p300 by CITED1, and reduces CITED1 binding to p300.
The mechanism by which these phosphorylation events influence binding to p300 is unclear as all of these sites are outside of the known, COOH-terminal CBP and p300 interaction domains of CITED1. One possibility is that phosphorylation of these sites alters the structural conformation of CITED1 in a way that conceals the p300 binding sites within its CR2 domain. Importantly, however, analysis of CITED1 mobility in p300 immunoprecipitates from cells overexpressing wild type CITED1 indicates that most of the CITED1 that interacts with p300 is in the unphosphorylated form. This suggests that induction of CITED1 phosphorylation decreases the amount of unphosphorylated CITED1 available to interact with, and activate p300 dependent responses. Whether these phosphorylation events also regulate other, as yet unidentified cytoplasmic functions of CITED1, is unknown.
Our studies raise a number of additional questions that remain to be addressed. For example, the kinases and/or phosphatases responsible for regulating these events are unknown, and the site and functional effects of CITED1 phosphorylation during mitosis has to be determined. Furthermore, the fact that CITED1 has been shown to be predominantly nuclear in some cells (including cultured melanocytes and virgin mammary epithelial cells) (13, 14) , and mixed cytoplasmic and nuclear in others (including thyroid carcinoma, melanoma and mammary duct epithelium) (17, 19, 23) , suggests that the subcellular localization of CITED1 may be dynamically regulated. Recent studies showing alterations in subcellular localization of CITED4 in invasive versus localized tumors of the breast (9) , suggest that this may represent a common mechanism regulating activities of different CITED family members.
In summary, we have shown for the first time that transcriptional activity CBP/p300-interacting cofactor CITED1 is dynamically regulated by cell cycle dependent phosphorylation, and that CITED1 phosphorylation reduces its ability to transactivate p300-dependent responses. As the pool of phosphorylated CITED1 is regulated as cells progress through different stages of the cell cycle, these findings suggest that alterations in CITED1 phosphorylation regulate its transcriptional activity.
